[Pegylation and interferons in multiple sclerosis]

[Pegylation and interferons in multiple sclerosis]

Pegylation is a procedure used for drug development since the 1970s and consists of the conjugation of a polyethylene glycol molecule (PEG) to a drug. PEG has shown to be safe and effective in improving the pharmacokinetic and pharmacodynamic profile of drugs. Recently, a 20 kDa linear chain of PEG...

Full description

Bibliographic Details
Main Authors:	Diego Centonze, Elisa Puma, Cecilia Saleri, Giulia Vestri, Sergio Iannazzo, Laura Santoni, Luigi Giuliani, Pier Luigi Canonico
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2016-07-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	peg interferon beta-1a plegridy half-life
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1229

Similar Items

[Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
by: Diego Centonze, et al.
Published: (2018-11-01)

Outcome of Pregnancy in the Era of PEGylated Interferon-α2a in Females with Chronic Myeloid Leukemia: An Experience from Qatar
by: Mohammad Abu-Tineh, et al.
Published: (2020-03-01)

by: Sergio lannazzo, et al.
Published: (2016-06-01)

Impacts of pegylated interferon-ribavirin combination treatment on thyroid functions and thyroid autoimmunity in patients with chronic hepatitis C
by: Ferhat Yılmaz, et al.
Published: (2010-09-01)

Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar
by: Mohammad Abu-Tineh, et al.
Published: (2020-03-01)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
by: Diego Centonze, et al.
Published: (2021-04-01)

Pegylated Interferons and Their Use in Clinical Practice
by: Alpay AZAP, et al.
Published: (2003-12-01)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
by: Elmazny A, et al.
Published: (2020-03-01)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
by: Wynn TT, et al.
Published: (2016-06-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
by: Masoud Mohammad Malekzadeh, et al.
Published: (2020-06-01)

Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a
by: N. A. Spirina, et al.
Published: (2018-02-01)

Regression of alveolar echinococcosis after chronic viral hepatitis C treatment with pegylated interferon alpha 2a
by: Dražilová S., et al.
Published: (2012-09-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
by: Dian HE, et al.
Published: (2014-09-01)

Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis
by: Guillermo Cabrera Álvarez, et al.
Published: (2007-10-01)

Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients
by: Xin Luo, et al.
Published: (2017-11-01)

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
by: Anuja Pandit, et al.
Published: (2021-04-01)

Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient with Multiple Sclerosis Treated with Interferon-Beta
by: Pegah Sadat Fatehi, et al.
Published: (2018-11-01)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
by: Megen C. Wittling, et al.
Published: (2021-01-01)

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
by: Masoud Etemadifar, et al.
Published: (2017-02-01)

Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report Interferon beta en polineuropatía crónica inflamatoria desmienlinizante: caso clínico
by: Andrés Maria Villa, et al.
Published: (2004-09-01)

Economic evaluation of the chronic hepatitis B treatment strategies in Italy
by: Sergio Iannazzo, et al.
Published: (2013-09-01)

Late onset of severe thrombocytopenia during interferon treatment for chronic hepatitis C infection: Case report
by: Hajder Jelena, et al.
Published: (2010-01-01)

Literature systematic review on the ophthalmological side effects of interferons
by: Yara Dadalti Fragoso, et al.
Published: (2011-08-01)

Higher Serum Uric Acid Levels in Multiple Sclerosis Patients After Longterm Interferon Beta Treatment
by: Toncev Gordana, et al.
Published: (2017-10-01)

Beta-interferons in multiple sclerosis: A single center experience in India
by: Gupta Salil, et al.
Published: (2010-01-01)

Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis
by: Ivanović Jovana, et al.
Published: (2019-01-01)

Erupção acneiforme aguda induzida por interferon beta-1b durante tratamento para esclerose múltipla Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis
by: Dário Júnior de Freitas Rosa, et al.
Published: (2011-04-01)

Recurrent Arthritis and Anti-cyclic Citrullinated Peptide Positivity during Interferon-beta 1a Treatment in Two Patients with Multiple Sclerosis
by: Hamed Cheraghmakani, et al.
Published: (2016-09-01)

Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial
by: Fereshteh Ashtari, et al.
Published: (2011-01-01)

Un método reproducible para obtener peg biramificado monofuncional de alta pureza A reproducible method for obtaining a 2-arms monofunctional peg with high purity
by: José A. Ramón, et al.
Published: (2009-01-01)

Prospective study of thyroid functions in multiple sclerosis patients treated with interferon beta in Alexandria University MS clinic
by: Farouk Talaat, et al.
Published: (2021-02-01)

The Effect of Beta Interferon on the Expression of miR-145 in Patients with Multiple Sclerosis
by: Naeim Ehtesham, et al.
Published: (2016-11-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
by: Miraç Ayşen Ünsal
Published: (2019-03-01)

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients
by: Sandra Phillips, et al.
Published: (2017-05-01)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Prediction of the Response to Pegylated Interferon α-2a in Patients with HBeAg Positive Chronic Hepatitis B through Decline of Serum HBV DNA and Hepatitis B Virus Surface Antigen at Week 4
by: Zheng Jian-ming, et al.
Published: (2012-12-01)

Insights Into Type I and III Interferons in Asthma and Exacerbations
by: Helen E. Rich, et al.
Published: (2020-09-01)

Significance of the interferon (IFN) in the therapy
by: Sabina Mahmutović, et al.
Published: (2004-11-01)